Abstract. On the basis of the gene expression profiles of 120 lung cancer cases using a cDNA microarray containing 27,648 genes or expressed sequence tags (ESTs), we identified LRRC42 (Leucine-rich repeat containing 42) to be significantly upregulated in the majority of lung cancers. Northern blot analysis demonstrated that LRRC42 was expressed only in testis among normal tissues examined. Knockdown of LRRC42 expression by siRNA against LRRC42 significantly suppressed the growth of lung cancer cells. On the other hand, stable induction of LRRC42 expression significantly promoted cell growth. LRRC42, which was found to localize in the nucleus of mammalian cells, is likely to interact with and stabilize GATAD2B (GATA zinc finger domain-containing 2B) and MBD3 (Methyl-CpG-binding domain protein 3) proteins that could contribute to lung cancer cell proliferation partly through the regulation of p21 Waf1/Cip1 . Our findings suggest that LRRC42 overexpression as well as its interaction with LRRC42-GATAD2B might play essential roles in lung carcinogenesis, and be a promising molecular target for lung cancer therapy.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide. Despite some advances in cancer diagnostics and recent improvements in its treatment, the overall 5-year survival rate is still only 15% (1) . Several oncogenic alterations, such as KRAS and EGFR mutations, and EML4-ALK fusion genes as well as inactivation of tumor suppressor gene of TP53 in lung cancer have been reported, however the precise molecular mechanisms of pulmonary carcinogenesis are still far from fully understood (2) . Although several molecular targeted-drugs such as gefitinib, bevacizumab and crizotinib have been approved for lung cancer treatment, the portion of patients who are able to have the benefit of these drugs is still limited and several serious adverse reactions such as interstitial pneumonia by gefitinib and hemorrhage by bevacizumab have been reported (3, 4) . Hence, the development of molecular targeted agents providing better clinical benefits with less adverse events are eagerly required.
Systematic analysis of expression levels of thousands of genes using a cDNA microarray is an effective technique to identify molecules involved in carcinogenic pathways (5) ; some of such genes or their gene products may be good molecular targets for the development of novel therapies and/or cancer biomarkers. To isolate potential molecular targets for diagnosis, treatment, and/or prevention of lung carcinomas, we performed a genome-wide analysis of gene expression profiles of tumor tissues from 120 lung cancer cases by means of cDNA microarray consisting of 27,648 genes or expressed sequence tags (ESTs) (6) (7) (8) (9) (10) . Among the transactivated genes, we identified LRRC42 (Leucine-rich repeat containing 42) as a potential therapeutic target for lung cancer. LRRC42 protein contains two leucine-rich repeats (LRRs) which are widespread structural motifs comprising 20-30 amino acids with a characteristic repetitive sequence pattern rich in leucine residues. Leucine-rich repeat domains are built from tandems of two or more repeats and form curved solenoid structures that are particularly suitable for protein-protein interactions. LRR-containing proteins participate in many important biological processes, including plant and animal immunity, hormone-receptor interactions, cell adhesion, signal transduction, regulation of gene expression and apoptosis (11) (12) (13) (14) . However, the pathophysiological roles of LRRC42 in cancer cells have not been reported. Herein we report identification of LRRC42 as a potential therapeutic target and also provide evidence that LRRC42 could interact with GATAD2B (GATA zinc finger domain containing 2B) and MBD3 (Methyl-CpG-binding domain protein 3) proteins that are likely to play a significant role in human pulmonary carcinogenesis. Waf1/Cip1 and GAPDH were designed as follows: LRRC42, 5'-TTGATCATAGTAACTGCAAGACAGAG-3' a nd 5'-ACG CTCCCACTG CAGA AC-3'; GA R A D2B, Immunofluorescence analysis. Cells were plated onto glass coverslips (Becton Dickinson, Mountain View, CA, USA), fixed with 4% paraformaldehyde, and permeablilized with 0.1% Triton X-100 in PBS for 5 min at room temperature. Non-specific binding was blocked by 5% skim milk for 10 min at room temperature. Cells were then incubated overnight at 4˚C with primary antibodies for mouse monoclonal anti-Flag antibody (Catalog no. F3165, Sigma, St. Louis, MO, USA) and anti-GATAD2B antibody (Catalog no. HPA017015, ATLAS, Stockholm, Sweden) diluted in PBS containing 1% BSA. After being washed with PBS, the cells were stained with Alexa Fluor 488-conjugated secondary antibody (Molecular Probes, Eugene, OR, USA) (Fig. 1C) , or with Alexa Fluor 488-conjugated secondary antibody and Alexa Fluor 594-conjugated secondary antibody (Molecular Probes) (Fig. 3C) for 60 min at room temperature. After another wash with PBS, each specimen was mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) containing 4', 6'-diamidine-2'-phenylindolendihydrochrolide (DAPI) and visualized with Spectral Confocal Scanning Systems (TSC SP2 AOBS: Leica Microsystems, Wetzlar, Germany).
Identification of a nuclear protein, LRRC42, involved in lung carcinogenesis
Northern blot analysis. Human multiple-tissue blots (Clontech, Carlsbad, CA, USA) were hybridized with 32 P-labeled PCR products of LRRC42. The cDNA probe of LRRC42 was prepared by RT-PCR using following primers: LRRC42, 5'-GACCAGATCGTTCTGCAGTG-3' and 5'-CCTCCCA CACCACAAAAGTA-3'. Prehybridization, hybridization, and washing were performed according to the supplier's recommendations. The blots were autoradiographed at -80˚C for 14 days.
RNA interference assay.
To evaluate the biological functions of LRRC42 in lung cancer cells, we used small interfering RNA (siRNA) duplexes against the target genes (Sigma). The target sequences of the synthetic oligonucleotides for RNA interference were as follows: control-1: [EGFP, enhanced green fluorescence protein (GFP) gene, a mutant of Aequorea gictoria GFP], 5'-GAAGCAGCACGACUUCUUC-3'; control-2 (LUC, luciferase gene from Photinus pyralis), 5'-CGUACG CGGAAUACUUCGA-3'; si-LRRC42-#1, 5'-CUUACUA CCUCAGCUCAGA-3'; si-LRRC42-#2, 5'-GACUUGUUA AAUUCCUAUU-3'; si-GATAD2B, 5'-GCCAAUAGCG AGUUCAUCU-3'; si-MBD3, 5'-CACAGUCGAGGCACG UCAU-3'. Lung cancer cell lines, LC319 and SBC-3, were plated onto 10-cm dishes (5.0x10 5 per dish), and transfected with either of the siRNA oligonucleotides (50 µM) using 30 µl of Lipofectamine ® RNAiMAX (Life Technologies) according to the manufacturers' instructions. After seven days of incubation, the cells were stained by Giemsa solution to assess colony formation, and cell numbers were assessed by Cell Counting Kit-8 (Dojindo Co., Kumamoto, Japan); briefly, Cell Counting Kit-8 solution was added to each dish at concentration of 1/10 volume, and the plates were incubated at 37˚C for additional 1 h. Absorbance was then measured at 490 nm, and at 630 nm as a reference, with a 2030 ARVO™ X3 (PerkinElmer, Courtaboeuf, France).
Anti-LRRC42 antibody. Plasmids expressing partial LRRC42 that contained His-tagged epitopes at their NH 2 termini were prepared using pET28 vector (Novagen, Darmstadt, Germany) and primers LRRC42-F (5'-GGAATTCTGGGCTGA CCAGATCGTTCTGC-3') and LRRC42-R (5'-ATAGTTT AGCGGCCGCTTAGTTATTCTGTTCTGTCTCTGACT-3'. Recombinant proteins were expressed in Escherichia coli BL21 codon-plus strain (Stratagene, San Diego, CA, USA) and purified using Ni-NTA (Qiagen) according to the supplier's protocol. The protein was inoculated into rabbits; immune sera were purified on affinity columns according to standard methods. Affinity-purified anti-LRRC42 antibodies were used for western blotting. We confirmed that the antibody was specific to LRRC42 on western blots using lysates from cell lines that had been transfected with LRRC42 expression vector.
Western blotting. Cells were lysed with immunoprecipitation assay buffer [50 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 1% NP40, 0.5% deoxychorate-Na, 0.1% SDS] containing Phosphatase Inhibitor Cocktail Set II and Protease Inhibitor Cocktail Set III EDTA-Free (Calbiochem, San Diego, CA, USA). Protein samples were separated by SDS-polyacrylamide gels and electroblotted onto Hybond-P PVDF membranes (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). Blots were incubated with a mouse monoclonal anti-Flag antibody, a rabbit anti-Flag antibody (Catalog no. F7425, Sigma), an anti-GATAD2B antibody, an anti-MBD3 antibody (Catalog no. sc-9402, Santa Cruz, Santa Cruz, CA, USA), an antip21
Waf1/Cip1 antibody (Catalog no. 2947S, Cell Signaling, Danvers, MA, USA) and an anti-p53 antibody (Catalog no. sc-126, Santa Cruz, Santa Cruz, CA, USA). Antigen-antibody complexes were detected using secondary antibodies conjugated to horseradish peroxidase (GE Healthcare Bio-Sciences). Protein bands were visualized by enhanced chemiluminescence western blot detection reagents (GE Healthcare Bio-Sciences).
Establishment of HEK293 cells expressing exogenous LRRC42. T-REx HEK293 cells that could induce the expression of exogenous LRRC42 (LRRC42-HEK293) cells were generated by Flp-In expression system, where LRRC42 expression is under control of the tetracycline-regulated cytomegalovirus/tetO 2 hybrid promoter, and the commercially available Flp-In T-REx 293 host cell line, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA).
Cell growth assay. LRRC42-HEK293 cells were grown for four days in DMEM containing 10% FBS, Blasticidin S HCl (Life Techonologies; 15 µg/ml) and Hygromycin B (Invitrogen; 100 µg/ml) supplemented with or without doxycycline (Sigma; 100 ng/ml). Viability of cells was evaluated by Cell Counting Kit-8. Tris-HCl, 150 mmol/l NaCl) in the presence of phosphatase and proteinase inhibitors. After centrifugation at 1,000 rpm for 5 min at 4˚C, the supernatants were incubated at 4˚C with anti-Flag M2 agarose for 3 h. The beads were then collected by centrifugation at 1,000 rpm for 1 min and washed six times with 1 ml of each immunoprecipitation buffer. The washed beads were resuspended in 30 µl of Laemmli sample buffer and boiled for 5 min, and the proteins were separated using 5% to 20% SDS PAGE gels (Bio-Rad Laboratories, Marnes-la-Coquette, France). After electrophoresis, the gels were stained with SilverQuest (Invitrogen). Protein bands specifically found in extracts which was transfected with LRRC42 vector were excised and served for matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) analysis (AXIMA-CFR, ShimadzuBiotech, Kyoto, Japan).
Flow cytometry. After transfection of each siRNAs, cells were treated with Aphidicolin (Sigma) at 1 µg/ml for 24 h. Then, the cells were washed with PBS four times and growth medium was added into the dish. The cells were collected in PBS every 3 h and fixed in 70% cold ethanol for 30 min. After treatment with 100 µg/ml of RNase (Sigma), the cells were stained with 50 µg/ml propidium iodide (Sigma) in PBS. Flow cytometry was analyzed by using FACScan (Becknman Coulter, Brea, CA, USA). The cells selected from at least 20,000 ungated cells were analyzed for DNA content.
Results

LRRC42 expression in lung cancers and normal tissues.
To identify novel target molecules for the development of therapeutic agents and/or diagnostic biomarkers for lung cancer, we previously performed gene expression profile analysis of 120 lung carcinoma samples using cDNA microarray containing 27,648 genes or expressed sequence tags (6-10), and identified that LRRC42 was significantly transactivated (more than 3 times higher than in their corresponding normal tissues) in >50% of 120 lung cancer samples examined. We subsequently confirmed its transactivation by quantitative real-time PCR experiments in lung cancer tissues as well as lung cancer cell lines (Fig. 1A and B) . Northern blot analysis with the LRRC42-specific probe identified a 1.7-kb transcript only in testis among 16 normal human tissues examined (Fig. 1C) . To determine the subcellular localization of LRRC42 protein, we constructed a plasmid expressing LRRC42 (carboxyl-terminal Flag-tagged pCAGGS plasmid vector), transfected it into COS-7 cells and detected exogenous LRRC42 protein in the nucleus of the cells using an anti-flag antibody (Fig. 1D) .
Effect of LRRC42 on cell growth. To assess whether LRRC42 is essential for growth or survival of lung cancer cells, we transfected synthetic oligonucleotide siRNAs against LRRC42 into lung adenocarcinoma LC319 and small cell lung cancer SBC-3 cells in which LRRC42 was highly expressed. The mRNA levels of LRRC42 in the cells transfected with si-LRRC42-#1 or -#2 were significantly decreased in comparison with those transfected with either of the control siRNAs ( Fig. 2A and B) . MTT and colony formation assays revealed a significant reduction of cell viability as well as the number of colonies in si-LRRC42-transfected cells (Fig. 2C-F) .
To further clarify a potential role of LRRC42 in carcinogenesis, we established HEK293 cells using the Flp-In T-Rex expression system, where LRRC42 expression was under the control of the tetracycline-regulated cytomegalovirus/tetO 2 hybrid promoter. MTT assay demonstrated that the growth of the cells treated with doxycycline was enhanced compared with that without doxycycline, indicating the growth promoting activity of LRRC42 protein ( Fig. 2G and H) .
Interaction and colocalization of LRRC42 with GATAD2B.
To elucidate the molecular mechanism of LRRC42 in lung carcinogenesis, we screened a protein(s) that could interact with LRRC42. Lysates of SBC-3 cells which was transfected with LRRC42 expression vector (carboxyl-terminal Flag-tagged pCAGGS plasmid vector) or mock vector were extracted, and immunoprecipitated with anti-Flag M2 agarose. The protein complex was separated by SDS-PAGE and visualized by silver staining (Fig. 3A) . A 65-kDa band, which was detectable in lysates of cells transfected with LRRC42 vector, but not in those with mock vector, was extracted. The peptide sequence analysis determined by mass spectrometry indicated the protein to be GATAD2B (GATA zinc finger domain containing 2B) that is known to be a component of the MeCP1 complex that represses transcription through preferential binding, remodeling and deacetylation of methylated nucleosomes (15) . We subsequently confirmed interaction between exogenous LRRC42 and endogenous GATAD2B in SBC-3 cells using anti-GATAD2B antibody by co-immunoprecipitation experiment (Fig. 3B) . We also conducted immunofluorescence analysis and found colocalization of exogenous LRRC42 with endogenous GATAD2B in the nucleus of SBC-3 cells which were transfected with the LRRC42 expression vector (Fig. 3C) . To further investigate the biological significance of the interaction between LRRC42 and GATAD2B in cancer cells, we examined the protein level of GATAD2B after suppressing LRRC42 expression in LC319 and SBC-3 cells. Treatment of siRNA oligonucleotides against LRRC42 (si-LRRC42) effectively knocked down the expression of endogenous LRRC42, compared to the control siRNA (si-EGFP). Interestingly, the protein level of GATAD2B was also significantly decreased in cells transfected with si-LRRC42, while the transcript level of GATAD2B was unchanged (Fig. 3D-I) . A previous study indicated GATAD2B as a key component of the MeCP1 complex that interacted with MBD3 (15). Furthermore, GATAD2B was shown to possess an ability to target MBD3 protein to specific nuclear loci (15, 46) . MBD3 was indicated to be recruited to a promoter region of the 21
Waf1/Cip1 tumor suppressor gene and silence its expression (47) . Hence, we have hypothesized that LRRC42 might have a very significant effect on the function of the MeCP1 complex through the interaction with GATAD2B as well as MBD3 (Fig. 3J) . We found that knockdown of LRRC42 or GATAD2B reduced the amount of MBD3 protein while no change was observed in mRNA level of MBD3 (Fig. 3K-N) .
LRRC42-GATAD2B-MBD3 axis regulates p21
Waf1/Cip1 expression. We then examined the downstream target of the LRRC42-GATAD2B-MBD3 complex in lung cancer cells. As described above, MBD3 might be recruited at the p21 Waf1/Cip1 promoter and silence its expression (47) . Therefore, we firstly assessed the knockdown effect of either of LRRC42, GATAD2B or MBD3 on p21
Waf1/Cip1 expression by quantitative real-time PCR and western blot analysis. Suppression of either of LRRC42, GATAD2B or MBD3 by siRNA appeared to increase p21
Waf1/Cip1 at transcriptional and protein levels in LC319 (p53 null) and SBC-3 (p53 wild-type) cells (Fig. 4A-D) . However, this effect on p21
Waf1/Cip1 was not clear in other lung cancer cell lines examined (NCI-H1781, NCI-H358, NCI-H1299 and DMS273; data not shown).
Since p21 Waf1/Cip1 expression was known to cause the G 0 /G 1 arrest, we performed FACS (Fluorescence Activated Cell Sorter) analysis to evaluate the knockdown effect on the cell cycle in these cell lines. After synchronization of the cancer cells at G 1 phase by aphidicolin, we removed aphidicolin from the cell culture medium and monitored the cell cycle progression process (Fig. 4E) . The cells transfected with si-EGFP progressed rapidly into the S and G 2 /M phases. However, the cells treated with siRNA against LRRC42, GATAD2B or MBD3 revealed significant delay in entering into S phase although the delay from the G 1 to S transition in the cells treated with si-MBD3 was less significant to those treated with siLRRC42 or si-GATAD2B. These data implied that the LRRC42-GATAD2B interaction may regulate MBD3 protein as well as the MeCP1 complex, and enhance the growth of cancer cells.
Discussion
Recent advances in understanding the molecular mechanisms underlying cancer development/progression have driven the design of new therapeutic approaches, termed 'molecular targeted therapies', that selectively interfere with molecules or pathways involved in tumor growth and progression.
Inactivation of growth factors and/or their receptors on tumor cells as well as the inhibition of oncogenic tyrosine kinase pathways that play crucial roles in cancer cells constitute the main rationale of new cancer treatments and also lead to the way for the personalized treatment for individual patients. Small-molecule inhibitors and monoclonal antibodies are at present major components of these targeted approaches for various types of human caner (16) . Molecular targeted cancer therapies hold the promise of being very selective to cancer cells, but not affecting normal cells. Hence, they are expected to be less harmful to normal cells, reduce severe side effects, and improve the quality of life of cancer patients. Toward identification of molecular targets for drug development, we had performed whole-genome expression profiles of 120 clinical lung cancer samples using cDNA microarray data and subsequent loss-of-function phenotype analyses by means of RNA interference systems . On the basis of this approach, we found LRRC42 to be highly over-expressed in the majority of clinical lung cancer cases as well as in most of the lung cancer cell lines examined, while its expression was absent in normal tissues except testis.
Furthermore, we demonstrated that knockdown of LRRC42 expression suppressed the growth of lung cancer cells. In addition, induction of LRRC42 expression by a T-REx system resulted in enhancement of cell growth, suggesting that LRRC42 is likely to be an important growth promoting factor in lung cancer cells and could serve as a valuable target for the development of an anticancer agent for lung cancer.
LRR family members were reported to participate in many biologically important processes such as hormone-receptor interactions, enzyme inhibition, cell adhesion and cellular trafficking. A number of studies clarified the involvement of LRR proteins in early mammalian development (39) , development of neuron (40) , cell polarization (41), regulation of gene expression (42) and apoptosis (43) . It was also shown that LRR domains may be critical for the cell morphology as well as the cytoskeleton dynamics (44, 45) . In these processes, the LRR motifs are probably essential in mediating protein-protein interactions. However, there has been no report describing the involvement of LRRC42 in human carcinogenesis.
Our data indicated that LRRC42 was able to interact with GATAD2B. GATAD2B is an important component of the MeCP1 complex that represses transcription of genes through preferential binding to, remodeling, and deacetylating methylated nucleosomes. It has the ability to translocate MBD3 protein to specific nuclear foci (15, 46) . We demonstrated that LRRC42 could activate this transcription-repressive complex through interacting with and stabilizing GATAD2B and MBD3 proteins. We also revealed that the LRRC42-GATAD2B-MBD3 interaction is likely to play a significant role in transcriptional regulation of the cyclin-dependent kinase inhibitor p21
Waf1/Cip1 which is a well-known tumor suppressor and an inhibitor of cell cycle progression from G 1 to S phase. p21
Waf1/Cip1 negatively regulates DNA replication through the interaction with PCNA (Proliferative cell nuclear antigen), and also binds to the CDK (Cyclin-dependent kinase) complex and inhibits the G 1 -S transition (48) .
Several transcriptional regulators, activators or repressors of p21
Waf1/Cip1 have been reported. p53 is an activator of p21
Waf1/Cip1 and the activation of the p53-p21 Waf1/Cip1 pathway is critically important when cells need to arrest the cell cycle and repair the DNA damage. Myc, one of p21 Waf1/Cip1 repressors, was reported to induce the expression of AP4 (Transcription Factor AP-4) that has the ability to repress p21
Waf1/Cip1 expression. Myc may also repress p21
Waf1/Cip1 expression through the interaction with MIZ1 (ZBTB17) (49) . MBD3 is known to be one of the repressors which directly regulate p21
Waf1/Cip1 expression and play important roles in oncogenic transformation and proliferation (50) . FACS analysis clearly demonstrated that suppression of MBD3 caused the delay of G 1 -S transition although its effect was not as significant as the knockdown of LRRC42 or GATAD2B.
In conclusion, human LRRC42 is essential for growth and survival of lung cancer cells. Our data imply that targeting LRRC42 and/or the LRRC42-GATAD2B interaction may be a good approach for development of new treatment of lung cancer with specific activity and minimum toxicity.
